Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02363998 · ClinicalTrials.gov registry record · Phase 3
Open-Label, Safety Study of Lofexidine
A Phase 3 study, sponsored by USWM, LLC (dba US WorldMeds).
- Completed
- Registry status
- Phase 3
- Development phase
- 286
- Enrollment target
NCT02363998 is a Phase 3 study that has completed, run by USWM, LLC (dba US WorldMeds). The registered enrollment target is 286 participants.
The verdict
NCT02363998, a Phase 3 study, has completed, sponsored by USWM, LLC (dba US WorldMeds).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 286 participants
- Enrollment target
Study Summary
The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and buprenorphine. This study will take place in a variety of clinical scenarios, both in-clinic and outpatient settings.
Interventions
- DRUG Lofexidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02363998
The ClinicalTrials.gov registry entry for NCT02363998 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is USWM, LLC (dba US WorldMeds), which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lofexidine is the first listed.
NCT02363998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02363998 about?
NCT02363998 is a clinical study titled "Open-Label, Safety Study of Lofexidine". The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and buprenorphine. This study will take place in a variety of clinical scenari...
What is the current status of trial NCT02363998?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 286 participants. The study started on 2015-02. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02363998?
The interventions under investigation include: Lofexidine (DRUG).
Who is sponsoring clinical trial NCT02363998?
This trial is sponsored by USWM, LLC (dba US WorldMeds), which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.